Last updated: February 16, 2026
Overview of the Drug
NDC 62332-0518 corresponds to the drug Doxorubicin Hydrochloride Injection. It is a cytotoxic agent used primarily in chemotherapy to treat various cancers, including breast cancer, bladder cancer, and lymphoma. The drug is supplied as a sterile aqueous solution for intravenous administration.
Current Market Landscape
Market Size and Key Players:
- The global oncology drug market was valued at approximately $175 billion in 2022, with chemotherapy agents representing around 40% of the segment. Doxorubicin remains a foundational chemotherapy component.
- Major manufacturers include Pfizer, Sandoz (Novartis), and Teva Pharmaceuticals. Pfizer's Doxorubicin is one of the most widely used brands.
- The drug faces competition from biosimilars and alternative chemotherapies, but Doxorubicin retains significant market share due to its established efficacy.
Regulatory Status:
- Licensed for use in multiple countries under different regulatory agencies (FDA, EMA, etc.).
- Patent protections for original formulations have expired; however, branded versions retain market dominance due to manufacturing quality and clinician preference.
Pricing Dynamics (2023):
- List Price: $190–$230 per 50 mg vial.
- Average Wholesale Price (AWP): Approximately $250 per vial.
- Reimbursement landscape: US Medicare and insurance reimbursements are typically aligned with AWP minus negotiated discounts.
Pricing Trends and Factors:
- Price stabilization due to high demand and limited biosimilar competition in the US.
- Slight reductions observed in European markets driven by biosimilar entry.
- Supply chain factors, manufacturing costs, and regulatory compliance influence pricing stability.
Market Drivers and Constraints:
- Drivers: Rising cancer incidence globally, expanding use in combination therapies, and ongoing clinical trials extending indications.
- Constraints: Generic competition, price caps in certain markets, and potential shifts to targeted therapies reducing demand for traditional chemotherapies.
Price Projections (2023–2028)
Baseline Assumptions:
- The market remains relatively stable with modest growth driven by increased cancer prevalence.
- Biosimilar penetration remains limited in the US but accelerates in Europe and Asia.
- Manufacturing costs are stable, with slight annual increases (2-3%) due to inflation and regulatory compliance.
| Year |
Price Range per 50 mg vial (USD) |
Notes |
| 2023 |
$190–$230 |
Current list and wholesale prices |
| 2024 |
$192–$235 |
Slight increase, biosimilars gain traction |
| 2025 |
$195–$240 |
Growing biosimilar competition, stabilization |
| 2026 |
$198–$245 |
Patent expirations for some formulations, price pressure continues |
| 2027 |
$200–$248 |
Increased biosimilar acceptance |
| 2028 |
$202–$250 |
Market stabilization but moderate price erosion |
Impacts on Price:
- The entry of biosimilars may reduce prices by 15–25% over five years in regions with rapid adoption.
- US market prices remain relatively stable due to limited biosimilar availability and high treatment thresholds.
Future Market Trends:
- Development of liposomal doxorubicin formulations, possibly affecting pricing.
- Potential price reductions associated with biosimilar approvals and increased competition.
Regulatory and Policy Impacts
- US policy discussions explore price caps and increased biosimilar incentivization.
- European Union continues to foster biosimilar uptake, aiming to reduce costs.
- Global pricing varies significantly based on regional policies and healthcare systems.
Key Takeaways
- NDC 62332-0518 corresponds to Doxorubicin Hydrochloride Injection, a key chemotherapy drug.
- The global market is stable but faces inevitable price pressures from biosimilar competition.
- US prices are high but relatively stable, with slight declines expected as biosimilars gain traction elsewhere.
- Over five years, price per vial is projected to increase gradually, with potential reductions linked to biosimilar adoption.
- Market growth driven by rising cancer rates and clinical use expansion, offset by competitive pressures.
FAQs
-
How does biosimilar entry impact doxorubicin pricing?
Biosimilar entry generally leads to significant price reductions—approximately 15–25% over five years—by increasing competition and offering lower-cost alternatives.
-
What are the main indications for NDC 62332-0518?
It is used to treat breast cancer, bladder cancer, lymphoma, and other malignancies where doxorubicin is indicated.
-
Are there market or regulatory risks affecting price stability?
Yes. Policy shifts toward price regulation, biosimilar approval delays, or supply chain disruptions could impact prices.
-
What factors influence US vs. international pricing?
US prices are higher due to less aggressive biosimilar adoption and higher reimbursement levels. International pricing is often regulated and varies by country, often lower due to government negotiation.
-
Could future formulations or delivery methods affect the market?
Yes. Liposomal or targeted delivery systems might influence demand and pricing, particularly if they demonstrate superior efficacy or safety profiles.
Citations
[1] IQVIA. (2022). Oncology Market Data.
[2] FDA. (2023). Approved Oncology Drugs.
[3] EvaluatePharma. (2023). Oncology Drugs Forecast.
[4] European Medicines Agency. (2023). Biosimilar Guidelines.
[5] Medicare.gov. (2023). Billing and Reimbursement Policies for Chemotherapy Agents.
